Free Trial

N4 Pharma (N4P) Competitors

N4 Pharma logo
GBX 0.36 -0.04 (-9.00%)
As of 06:12 AM Eastern

N4P vs. CEL, HELD, HLN, BXP, HIK, HCM, INDV, AMYT, APH, and AGY

Should you be buying N4 Pharma stock or one of its competitors? The main competitors of N4 Pharma include Celadon Pharmaceuticals (CEL), Hellenic Dynamics (HELD), Haleon (HLN), Beximco Pharmaceuticals (BXP), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Alliance Pharma (APH), and Allergy Therapeutics (AGY). These companies are all part of the "drug manufacturers - specialty & generic" industry.

N4 Pharma vs.

Celadon Pharmaceuticals (LON:CEL) and N4 Pharma (LON:N4P) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, community ranking, earnings and institutional ownership.

In the previous week, Celadon Pharmaceuticals' average media sentiment score of 0.00 equaled N4 Pharma'saverage media sentiment score.

Company Overall Sentiment
Celadon Pharmaceuticals Neutral
N4 Pharma Neutral

Celadon Pharmaceuticals has a net margin of -4,024.62% compared to N4 Pharma's net margin of -18,399.86%. N4 Pharma's return on equity of -90.68% beat Celadon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Celadon Pharmaceuticals-4,024.62% -187.26% -34.40%
N4 Pharma -18,399.86%-90.68%-56.00%

N4 Pharma has lower revenue, but higher earnings than Celadon Pharmaceuticals. N4 Pharma is trading at a lower price-to-earnings ratio than Celadon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celadon Pharmaceuticals£123.38K33.70-£4.97M-£7.98-0.85
N4 Pharma£8.84K177.31-£1.63M-£0.35-1.05

Celadon Pharmaceuticals has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, N4 Pharma has a beta of -0.37, meaning that its share price is 137% less volatile than the S&P 500.

N4 Pharma received 99 more outperform votes than Celadon Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Celadon Pharmaceuticals an outperform vote while only 65.61% of users gave N4 Pharma an outperform vote.

CompanyUnderperformOutperform
Celadon PharmaceuticalsOutperform Votes
4
100.00%
Underperform Votes
No Votes
N4 PharmaOutperform Votes
103
65.61%
Underperform Votes
54
34.39%

10.7% of Celadon Pharmaceuticals shares are owned by institutional investors. 65.1% of Celadon Pharmaceuticals shares are owned by company insiders. Comparatively, 18.0% of N4 Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Celadon Pharmaceuticals beats N4 Pharma on 8 of the 13 factors compared between the two stocks.

Get N4 Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

N4P vs. The Competition

MetricN4 PharmaDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£1.57M£2.18B£5.35B£2.51B
Dividend Yield3.12%2.92%5.44%4.96%
P/E Ratio-1.054.3121.96131.81
Price / Sales177.31467.91396.51238,154.20
Price / Cash2.2510.2538.2028.05
Price / Book0.816.486.734.49
Net Income-£1.63M£20.70B£3.21B£5.82B
7 Day Performance-5.45%1.28%3.97%1.44%
1 Month Performance-24.01%-3.17%-7.03%5.26%
1 Year Performance-55.88%94.31%15.46%101.08%

N4 Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
N4P
N4 Pharma
N/AGBX 0.36
-9.0%
N/A-52.9%£1.57M£8,841.37-1.055
CEL
Celadon Pharmaceuticals
N/AGBX 6.40
-1.5%
N/A-94.1%£3.93M£123,381.65-0.802,780Gap Down
HELD
Hellenic Dynamics
N/AGBX 0.95
flat
N/AN/A£1.40MN/A-0.27N/A
HLN
Haleon
1.2547 of 5 stars
GBX 380.50
-0.6%
GBX 457
+20.1%
+14.4%£34.34B£11.07B32.0025,408News Coverage
Positive News
BXP
Beximco Pharmaceuticals
N/AGBX 39
+2.6%
N/A+6.8%£26.59B£7.08T4.185,500
HIK
Hikma Pharmaceuticals
3.4706 of 5 stars
GBX 1,885
-0.3%
GBX 2,436.67
+29.3%
+4.7%£5.23B£3.74B18.509,100
HCM
HUTCHMED
N/AGBX 212
+2.4%
N/A-20.0%£2.30B£771.01M-54.111,760News Coverage
Gap Up
INDV
Indivior
1.6458 of 5 stars
GBX 688.50
+1.0%
GBX 1,650
+139.7%
-54.3%£1.08B£1.40B-570.871,000News Coverage
Gap Up
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24M-4.33290Gap Down
APH
Alliance Pharma
1.823 of 5 stars
GBX 64.20
flat
GBX 6,250
+9,635.2%
+81.1%£347.61M£183.50M-10.3591,000
AGY
Allergy Therapeutics
N/AGBX 5.80
+1.8%
N/A+130.4%£285.07M£72.18M-5.59612News Coverage
Gap Up

Related Companies and Tools


This page (LON:N4P) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners